TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib
Clinical trial NCT04173585 · COMPLETED
Trial details
- NCT number
- NCT04173585
- Sponsor
- University Hospital Heidelberg
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-22
- Primary completion
- 2023-02-28
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.